Sichuan Jishengtang Pharmaceutical Co., Ltd.

Phase 2b Trial Met Primary Endpoint, Demonstrating Strong Efficacy and Favorable Safety Profile; Phase 3 Planned CHENGDU, China and ROCKAWAY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Kanghong Pharmaceutical and Vanotech Ltd. today announced the successful completion of a Phase 2b clinical trial evaluating KH607 in adults with major depressive disorder (MDD). HIGHLIGHTS Phase 2b trial successfully completed in adults with MDD Study met primary endpoint and demonstrated strong efficacy Rapid, robust, and sustained antidepressant effects observed Favorable safety and tolerability pro no serious safety concerns Phase 3 clinical development planned The Phase 2b study met its primary endpoint, with results demonstrating strong efficacy and a favorable safety profile. KH607 exhibited rapid, robust, and sustained antidepressant effects, reinforcing its potential as a promising new treatment option for patients with MDD. KH607 was generally well tolerated, with no serious safety concerns identified during the trial. Its overall safety pro continued clinical development and advancement into later-stage studies. “These results mark an important milestone for KH607 and provide strong validation of its therapeutic potential in MDD,” said Avner Ingerman, MD, President and Chief Medical Officer of Vanotech, Ltd. “We are encouraged by the combination of efficacy and tolerability observed in this study.” Based on these positive outcomes, the companies plan to advance KH607 into Phase 3 development. About KH607 KH607 is an investigational oral small molecule and positive allosteric modulator (PAM) of the GABAₐ receptor. It is designed to selectively target receptor subtypes implicated in mood regulation. KH607 is being developed for the treatment of major depressive disorder (MDD) and other neuropsychiatric conditions. About Major Depressive Disorder (MDD) Major depressive disorder (MDD) is a common and serious mental health condition affecting more than 280 million people worldwide. It is characterized by persistent low mood, loss of interest, and a range of cognitive and physical symptoms that impair daily functioning. Despite available therapies, many patients fail to achieve adequate response or remission, underscoring the need for new treatment options. About Kanghong Pharmaceutical Kanghong Pharmaceutical is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies addressing unmet medical needs. The company maintains a diversified pipeline across multiple therapeutic areas, supported by integrated research, development, and manufacturing capabilities. About Vanotech Ltd. Vanotech Ltd. is a clinical-stage biopharmaceutical company responsible for the global clinical development of KH607 and other pipeline assets. Headquartered in Rockaway, New Jersey, Vanotech collaborates with partners to advance novel therapies for central nervous system and other disorders. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the clinical development, therapeutic potential, and planned advancement of KH607. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on these forward-looking statements. The companies undertake no obligation to update any forward-looking statements, except as required by law. Investor & Media Contacts Kanghong Pharmaceutical Corporate Planning Department Email: qhb@cnkh.com Phone: +86-136-2805-8888 Vanotech Ltd. Matthew Schiller Email: matt.schiller@cnkh.com Phone: +1-617-510-9271

BioDlink received a formal letter of appreciation from Chengdu Kanghong Pharmaceutical Group for its contribution to advancing KH815, the world's first dual-payload antibody –drug conjugate (ADC) to enter clinical development. BioDlink enabled IND approval 1.5 months ahead of schedule through efficient process development, manufacturing, and analytical execution. SUZHOU, China, Feb. 9, 2026 /PRNewswire/ -- BioDlink announced that it has received a formal letter of appreciation from its client, Chengdu Kanghong Pharmaceutical Group ("Kanghong Pharmaceutical"), recognizing BioDlink's critical contribution to the successful clinical approval of KH815, the world's first dual-payload antibody–drug conjugate (ADC) to enter clinical development. KH815 is a first-in-class dual-payload ADC independently developed by Kanghong Pharmaceutical. The program achieved a major regulatory milestone with approval from Australia's Human Research Ethics Committee (HREC) on March 21, 2025 followed by clinical trial authorization in China on April 15, 2025. As Kanghong Pharmaceutical's CDMO partner, BioDlink supported the program across the full development lifecycle, including process development, analytical method development and validation, and formulation research. Efficient Execution of a Complex First-in-Class Program KH815 required advanced process design and analytical control, including precise management of drug-to-antibody ratio (DAR) and comprehensive product characterization. Leveraging its expertise in complex ADC development, BioDlink delivered a robust, scalable, and reproducible manufacturing solution despite limited material availability and aggressive timelines. Despite the complexity of conjugation process development and analytical characterization, BioDlink applied strong technical expertise to define and lock robust process and analytical strategies, enabling successful scale-up and batch release. Through continuous process optimization, development, manufacturing, and regulatory submission activities were completed 1.5 months ahead of plan, exceeding client expectations and demonstrating strong execution capability, which earned high recognition from Kanghong Pharmaceutical for BioDlink's technical expertise and service excellence. Advancing Innovation in ADC Development The successful progression of KH815 underscores the growing potential of dual-payload ADC technologies and highlights the value of close collaboration across industry and research. BioDlink remains committed to providing end-to-end CDMO services to global partners, accelerating the development of complex biologics from early development through commercialization. About Kanghong Pharmaceutical Kanghong is a publicly traded pharmaceutical company based in the province of Sichuan, China. It was founded in 1996 and researches, develops, manufactures, and distributes medicines for ophthalmic, neuropsychiatric and others. Kanghong is devoted to the lives of patients through high quality, innovation and responsibility. Since its establishment, the company keeps researching, producing, and commercializing safer and more efficient drugs for pressing unmet medical needs. The company's purpose is to fundamentally improve patients' physical ability and social medical efficacy by using innovative science and breakthrough treatments to achieve progress in human health. About BioDlink BioDlink (1875.HK) is a leading global CDMO specializing in biologics and bioconjugates (ADCs/XDCs). Headquartered in Suzhou with centers in Shanghai and Beijing, the company provides fully integrated, end-to-end services spanning early R&D through commercial manufacturing. With its one-base integrated platform and proprietary technologies—such as BDKcell® for rapid cell line development and GL-DisacLink® for site-specific conjugation—BioDlink helps partners accelerate development, improve efficiency, and reduce costs. The company operates four commercial manufacturing lines with large-scale sterile fill-finish capabilities, backed by a global GMP-aligned quality system that has earned PMDA accreditation in Japan and supported product approvals across China, Indonesia, Nigeria, Pakistan, Colombia and Bolivian. Guided by the philosophy of "Quality First, Innovation Driven, Success Together", BioDlink is committed to advancing global access to next-generation biologics and building trusted partnerships worldwide. For more information, please visit: SOURCE BioDlink Biopharm Co., Ltd. 21% more press release views with Request a Demo